Mani,
The reason I bring up mass media coverage has to do with what I've seen happen previously.
Have you been around long enough to know about Judah Folkman. The NY Times wrote him up many years ago, with headlines that if left alone he could cure cancer in 2 years. The company he worked for was about $1 at the time, it went above $100 before falling back to earth when people realized that to date, he was only curing mice. Clearly the Times overstated what he was doing, in the end I believe it failed completely.
My point is, you never know what will happen if you get the right coverage.
We have a product, DCVax-L, which potentially can have tremendous benefits in many forms of solid cancers. I would suspect that in a fair number of patients with different forms of cancer it may make the difference between reasonable lengthy remissions, and cures. The NY Times said cures when it was just mice, I frankly don't know if some of our 5 year plus survivors of GBM have been called cured by their Drs. If they have been, it wouldn't be an exaggeration to say we're curing GBM patients, but even if that determination hasn't been made, what if the mass media says it has. What if they also state that in compassionate use benefits have been seen in the likes of pancreatic, lung, breast, etc.
I'm not saying this will happen, though it's true, but what if it did. What if every major network ran stories about it. Lots of news agencies jumped on the Judah Folkman article years ago, what if we got that sort of coverage.
Don't get me wrong, at this point $5 is probably at the high end of what might be sustained, roughly a $7 billion market cap, and it's probably no more than $5 billion, but that doesn't put a cap on how high it could go on emotion with the right media coverage.
Everyone can decide for themselves, but once the share price exceeds somewhere in the $5 to $10 range, I'll be placing trailing stop losses and raising them as the price moves higher.
As for what it would take to sustain $10 or more, I think it's possible with EDEN acceptance and submission to the regulators, but likely after one or more of the other regulators approve, especially if we're achieving a tumor agnostic label.
Whether we get a tumor agnostic label, or not, by late 2027 I think enough will be known from new trials that DCVax-L will be used, and authorized by insurance, in many of the deadliest cancers, and by then earnings will be at least a few billion and a P/E of 30 or more will be earned because of rapid earnings growth, That could give us high double to triple digit billion market caps. Assuming 2 billion shares outstanding we're still looking at $40 or more a share by then.
Gary
Bullish
AI
Market Data 
Markets 
